SEC Charges Cassava Sciences Over Manipulated Alzheimer's Trial …
WEB3 days ago — Alzheimer’s drug developer Cassava Sciences Inc (NASDAQ:SAVA), its founder Remi Barbier, and former Senior VP of Neuroscience Lindsay Burns have agreed to pay over $40 million to resolve SEC ...
Company misled investors on possible Alzheimer’s drug, SEC …
WEB7 hours ago — The troubled biopharma company Cassava Sciences agreed last week to pay $40 million to settle U.S. Securities and Exchange Commission (SEC) charges that it had misled investors about early clinical results for its experimental Alzheimer’s disease drug, simufilam. The compound is now in pivotal phase 3 trials, but SEC’s announcement may …
Cassava pays $40M over allegedly misleading Alzheimer's update
WEB3 days ago — Cassava, former execs ink SEC deal to resolve allegations around misleading Alzheimer's data drop. Cassava Sciences has agreed to pay $40 million to resolve an investigation into claims it made ...
Cassava's Stock Drops After It Agrees to Pay $40M to Settle SEC ...
WEB3 days ago — Cassava Sciences (SAVA) shares dropped more than 11% after the company agreed to a $40 million settlement with the Securities and Exchange Commission (SEC) over charges that it manipulated ...
SEC Announces $40 Mln Settlement With Cassava Sciences Over …
WEB3 days ago — Without admitting or denying the allegations, Cassava, Barbier, and Burns consented to civil injunctions against future violations and agreed to pay civil penalties of $40 million, $175,000, and ...
Cassava to Pay $40 Million to SEC Over Alzheimer’s Drug Claims
WEB3 days ago — Drugmaker Cassava Sciences Inc. and two former executives agreed to pay more than $40 million to resolve US Securities and Exchange Commission claims they misled the public about the success of an Alzheimer’s drug trial.. Cassava published results in 2020 based on hand-selected data that showed patients’ memories improved, though …
Cassava Sciences and former execs agree to SEC fines | STAT
WEB4 days ago — Sept. 26, 2024. West Coast Biotech & Life Sciences Reporter. Facing charges from the Securities and Exchange Commission for misleading claims related to a controversial Alzheimer’s drug ...
Cassava Sciences Resolves SEC Investigation - GlobeNewswire
WEB4 days ago — AUSTIN, Texas, Sept. 26, 2024 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (“Cassava” or the “Company”) (Nasdaq: SAVA), a biotechnology company focused on Alzheimer’s disease, today ...
US charges Cassava Sciences, two former executives for ... - Yahoo
WEB4 days ago — WASHINGTON (Reuters) -Shares of Cassava Sciences fell 10% in post-market trading on Thursday after the U.S. Securities and Exchange Commission charged the biopharmaceutical company and two former ...
PRESS RELEASES - Cassava Sciences, Inc.
WEBJun 28, 2024 — Cassava Sciences Mourns the Death of Board Member Sanford “Sandy” Robertson. AUSTIN, Texas , Aug. 05, 2024 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (Nasdaq: SAVA) today reflected on the passing …
- Some results have been removed